Ellipticine HCl | CAS# 5081-48-1 | Apoptosis Inducer

MedKoo Cat#: 565369 | Name: Ellipticine HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ellipticine is a DNA intercalating agent and a DNA topoisomerase II inhibitor. Ellipticine is an alkaloid first extracted from trees of the species Ochrosia elliptica and Rauvolfia sandwicensis,[5][6] which inhibits the enzyme topoisomerase II via intercalative binding to DNA. Ellipticine is a known intercalator, capable of entering a DNA strand between base pairs. In its intercalated state, ellipticine binds strongly[9] and lies parallel to the base pairs, increasing the superhelical density of the DNA. Intercalated ellipticine binds directly to topoisomerase II, an enzyme involved in DNA replication, inhibiting the enzyme and resulting in powerful antitumour activity.

Chemical Structure

Ellipticine HCl

CAS#5081-48-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 565369

Name: Ellipticine HCl

CAS#: 5081-48-1 (HCl)

Chemical Formula: C17H15ClN2

Exact Mass: 282.0924

Molecular Weight: 282.77

Elemental Analysis: C, 72.21; H, 5.35; Cl, 12.54; N, 9.91

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 400.00	2 Weeks
100mg	USD 700.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,050.00	2 Weeks
1g	USD 3,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

519-23-3 (free base) 5081-48-1 (HCl) 55042-50-7 (tartrate)

Synonym

Ellipticine Hydrochloride; Ellipticine HCl; CCG-36483; CCG36483; CCG 36483; DB-052047; K00071; LP00531; LS-133282; NSC 71795; NSC71795; NSC-71795; TCMDC-125546; VZ29809; Elliptecine; Ellipticine; Elliptisine.

IUPAC/Chemical Name

5,11-Dimethyl-6H-pyrido[4,3-b]carbazole hydrochloride

InChi Key

VSBNVARERCGCEF-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H14N2.ClH/c1-10-14-9-18-8-7-12(14)11(2)17-16(10)13-5-3-4-6-15(13)19-17;/h3-9,19H,1-2H3;1H

SMILES Code

CC1=C(C=NC=C2)C2=C(C)C(N3)=C1C4=C3C=CC=C4.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Ellipticine (NSC 71795) hydrochloride is a potent antineoplastic agent; inhibits DNA topoisomerase II activities.

In vitro activity:

Ellipticine treatment significantly inhibited the viability and proliferation of RA-FLSs (rheumatoid arthritis fibroblast-like synoviocytes) in a concentration-dependent manner. In contrast, ellipticine exposure did not alter the viability of normal human FLSs. Moreover, ellipticine triggered significant apoptosis and increased caspase-3 activity in RA-FLSs. Mechanistically, ellipticine reduced the phosphorylation of STAT3 and downregulated the expression of Mcl-1, cyclin D1 and Bcl-2. Luciferase reporter assay demonstrated that ellipticine treatment led to a significant inhibition of STAT3-mediated transcriptional activity in RA-FLSs. Overexpression of constitutively active STAT3 reversed the suppressive effects of ellipticine on RA-FLSs, which was accompanied by restoration of Mcl-1, cyclin D1 and Bcl-2. Reference: Immunopharmacol Immunotoxicol. 2017 Aug;39(4):219-224. https://www.tandfonline.com/doi/abs/10.1080/08923973.2017.1327963?journalCode=iipi20

In vivo activity:

The capacity of ellipticine to form DNA adducts was investigated in vivo. Male Wistar rats were treated with ellipticine, and DNA from various organs was analyzed by (32)P postlabeling. Ellipticine-specific DNA adduct patterns were detected in most test organs. The highest level of DNA adducts was found in liver (19.7 adducts per 10(7) nucleotides), followed by spleen, lung, kidney, heart and brain. One major and one minor ellipticine-DNA adducts were found in DNA of all these organs of rats exposed to ellipticine. The predominant adduct formed in rat tissues in vivo was identical to the deoxyguanosine adduct generated in DNA by ellipticine in vitro as shown by cochromatography in 2 independent systems. Correlation studies showed that the formation of this major DNA adduct in vivo is mediated by CYP3A1- and CYP1A-dependent reactions. The results show the formation of CYP-mediated covalent DNA adducts by ellipticine in vivo and confirm the formation of covalent DNA adducts as a new mode of ellipticine action. Reference: Int J Cancer. 2003 Dec 20;107(6):885-90. https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.11511

	Solvent	mg/mL	mM
Solubility
	DMSO	4.4	15.56

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 282.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wen HL, Yang G, Dong QR. Ellipticine inhibits the proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes via the STAT3 pathway. Immunopharmacol Immunotoxicol. 2017 Aug;39(4):219-224. doi: 10.1080/08923973.2017.1327963. Epub 2017 May 30. PMID: 28555524. 2. Chen Q, Liu J, Zhuang Y, Bai LP, Yuan Q, Zheng S, Liao K, Khan MA, Wu Q, Luo C, Liu L, Wang H, Li T. Identification of an IKKβ inhibitor for inhibition of inflammation in vivo and in vitro. Pharmacol Res. 2019 Nov;149:104440. doi: 10.1016/j.phrs.2019.104440. Epub 2019 Aug 31. PMID: 31479750. 3. Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling. Int J Cancer. 2003 Dec 20;107(6):885-90. doi: 10.1002/ijc.11511. PMID: 14601046.

In vitro protocol:

In vivo protocol:

1. Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling. Int J Cancer. 2003 Dec 20;107(6):885-90. doi: 10.1002/ijc.11511. PMID: 14601046. 2. Chen Q, Liu J, Zhuang Y, Bai LP, Yuan Q, Zheng S, Liao K, Khan MA, Wu Q, Luo C, Liu L, Wang H, Li T. Identification of an IKKβ inhibitor for inhibition of inflammation in vivo and in vitro. Pharmacol Res. 2019 Nov;149:104440. doi: 10.1016/j.phrs.2019.104440. Epub 2019 Aug 31. PMID: 31479750.

1: Lu H, Liu M, Lu W, Wang C, Wang G, Dong W, Wang X, Chen H, Tan C. Repurposing Ellipticine Hydrochloride to Combat Colistin-Resistant Extraintestinal Pathogenic E. coli (ExPEC). Front Microbiol. 2020 May 25;11:806. doi: 10.3389/fmicb.2020.00806. PMID: 32528422; PMCID: PMC7262907. 2: Costa de Oliveira R, Soares Pontes G, Kostyuk A, Coutinho Camargo GB, Dhyani A, Shvydenko T, Shvydenko K, Grafov A. Anticancer and Immunomodulatory Activities of a Novel Water-Soluble Derivative of Ellipticine. Molecules. 2020 May 1;25(9):2130. doi: 10.3390/molecules25092130. PMID: 32370100; PMCID: PMC7248987. 3: Li X, Ye C, Mulati M, Sun L, Qian F. Ellipticine blocks synergistic effects of IL-17A and TNF-α in epithelial cells and alleviates severe acute pancreatitis-associated acute lung injury. Biochem Pharmacol. 2020 Jul;177:113992. doi: 10.1016/j.bcp.2020.113992. Epub 2020 Apr 23. PMID: 32335141. 4: Zencir S, Hsieh MH, Hsu JS, Ergun Y, Chou GL, Li TK, Teng SC, Topcu Z. Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells. J Cancer Res Clin Oncol. 2020 Jul;146(7):1671-1676. doi: 10.1007/s00432-020-03213-x. Epub 2020 Apr 24. PMID: 32333143. 5: Márquez E, Mora JR, Flores-Morales V, Insuasty D, Calle L. Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study. Molecules. 2019 Dec 19;25(1):24. doi: 10.3390/molecules25010024. PMID: 31861689; PMCID: PMC6982814. 6: Tian LX, Li XY, Tang X, Zhou XY, Luo L, Ma XY, Tang WQ, Yu J, Ma W, Yang X, Yan J, Xu X, Liang HP. Ellipticine Conveys Protective Effects to Lipopolysaccharide-Activated Macrophages by Targeting the JNK/AP-1 Signaling Pathway. Inflammation. 2020 Feb;43(1):231-240. doi: 10.1007/s10753-019-01112-z. PMID: 31802382. 7: Dan VM, Varghese TS, Viswanathan G, Baby S. Ellipticine, its Derivatives: Re- evaluation of Clinical Suitability with the Aid of Drug Delivery Systems. Curr Cancer Drug Targets. 2020;20(1):33-46. doi: 10.2174/1568009619666190927150131. PMID: 31560288. 8: Dilek Ö, Patir S, Tilki T, Ertürk E. Total Synthesis of Olivacine and Ellipticine via a Lactone Ring-Opening and Aromatization Cascade. J Org Chem. 2019 Jun 21;84(12):7901-7916. doi: 10.1021/acs.joc.9b00706. Epub 2019 Jun 5. PMID: 31117560. 9: Lin J, Tang M, Zhao R, Du Q, Shen L, Du G, Zhang Y, Li Y, Pan X. Synthetic Optimization of Ellipticine and Antitumor Activity of Novel Hexacyclic Derivatives of Ellipticine. Curr Pharm Des. 2019;25(33):3578-3589. doi: 10.2174/1381612825666190404122650. PMID: 30947658. 10: Indra R, Černá T, Heger Z, Hraběta J, Wilhelm M, Dostálová S, Lengálová A, Martínková M, Adam V, Eckschlager T, Schmeiser HH, Arlt VM, Stiborová M. Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells. Toxicology. 2019 May 1;419:40-54. doi: 10.1016/j.tox.2019.03.009. Epub 2019 Mar 23. PMID: 30914192. 11: Kolarik M, Indra R, Adam V, Heger Z, Kopeckova K, Arlt VM, Stiborova M. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro. Neuro Endocrinol Lett. 2019 Feb;39(7):515-524. PMID: 30860683. 12: Reed L, Indra R, Mrizova I, Moserova M, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM. Application of hepatic cytochrome b5/P450 reductase null (HBRN) mice to study the role of cytochrome b5 in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine. Toxicol Appl Pharmacol. 2019 Mar 1;366:64-74. doi: 10.1016/j.taap.2019.01.020. Epub 2019 Jan 25. PMID: 30685480; PMCID: PMC6382462. 13: Zsila F, Samsonov SA. Molecular interactions of the anticancer agent ellipticine with glycosaminoglycans by in silico analysis. Carbohydr Res. 2018 Jun 15;462:28-33. doi: 10.1016/j.carres.2018.03.014. Epub 2018 Apr 3. PMID: 29655053. 14: Cerna T, Hrabeta J, Eckschlager T, Frei E, Schmeiser HH, Arlt VM, Stiborová M. The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells. Int J Mol Sci. 2018 Jan 5;19(1):164. doi: 10.3390/ijms19010164. PMID: 29304031; PMCID: PMC5796113. 15: Stiborová M, Indra R, Frei E, Kopečková K, Schmeiser HH, Eckschlager T, Adam V, Heger Z, Arlt VM, Martínek V. Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine. Monatsh Chem. 2017;148(11):1983-1991. doi: 10.1007/s00706-017-1986-9. Epub 2017 Jul 4. PMID: 29104319; PMCID: PMC5653753. 16: Wen HL, Yang G, Dong QR. Ellipticine inhibits the proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes via the STAT3 pathway. Immunopharmacol Immunotoxicol. 2017 Aug;39(4):219-224. doi: 10.1080/08923973.2017.1327963. Epub 2017 May 30. PMID: 28555524. 17: Kumarasamy VM, Sun D. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative. Int J Oncol. 2017 Jul;51(1):145-157. doi: 10.3892/ijo.2017.3994. Epub 2017 May 11. PMID: 28498409; PMCID: PMC5467785. 18: Nishiyama T, Hatae N, Mizutani M, Yoshimura T, Kitamura T, Miyano M, Fujii M, Satsuki N, Ishikura M, Hibino S, Choshi T. Concise synthesis and antiproliferative activity evaluation of ellipticine quinone and its analogs. Eur J Med Chem. 2017 Aug 18;136:1-13. doi: 10.1016/j.ejmech.2017.04.071. Epub 2017 Apr 28. PMID: 28477443. 19: Sulc M, Mrizova I, Cerna T, Frei E, Eckschlager T, Adam V, Kopeckova K, Stiborova M. Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine. Neuro Endocrinol Lett. 2016 Dec 18;37(Suppl1):95-102. PMID: 28263536. 20: Tao S, Meng S, Zheng X, Xie L. ATM participates in the regulation of viability and cell cycle via ellipticine in bladder cancer. Mol Med Rep. 2017 Mar;15(3):1143-1148. doi: 10.3892/mmr.2017.6141. Epub 2017 Jan 24. PMID: 28138703; PMCID: PMC5367361.